Pityriasis Rubra Pilaris Response to IL-17A Inhibition Is Associated with IL-17C and CCL20 Protein Levels

J Invest Dermatol. 2022 Jan;142(1):235-239.e1. doi: 10.1016/j.jid.2021.06.009. Epub 2021 Jul 9.

Affiliations

¹ Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
² Department of Biostatistics, Mailman School of Public Health, Columbia University, New York City, New York, USA.
³ Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA. Electronic address: [email protected].

PMID: 34246621
DOI: 10.1016/j.jid.2021.06.009

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Adult
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Chemokine CCL20 / metabolism*
Female
High-Throughput Screening Assays
Humans
Inflammation Mediators / metabolism
Interleukin-17 / metabolism*
Male
Middle Aged
Pityriasis Rubra Pilaris / drug therapy
Pityriasis Rubra Pilaris / immunology*
Proteomics
Skin / pathology*

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal, Humanized
Chemokine CCL20
IL17C protein, human
Inflammation Mediators
Interleukin-17
ixekizumab